Literature DB >> 2788468

CML-T1: a cell line derived from T-lymphocyte acute phase of chronic myelogenous leukemia.

K Kuriyama1, R P Gale, M Tomonaga, S Ikeda, E Yao, I Klisak, K Whelan, H Yakir, M Ichimaru, R S Sparkes.   

Abstract

Most data suggest that malignant transformation in chronic myelogenous leukemia (CML) occurs in hematopoietic stem cell that is the progenitor of myelopoiesis and of B but not T lymphopoiesis. We established a T-lymphoid cell line (CML-T1) from a person with Ph-chromosome-negative CML in acute phase. Evidence of its T-lymphocyte origin includes the pattern cytochemical reactivity, reactivity with anti-T-cell monoclonal antibodies (MoAbs), and rearrangement of the beta-T-cell receptor (TCRB) gene. CML-T1 cells have features of type IV thymocytes. Cytogenetic analyses indicate a 47,XX, del(11), t(6;7)(q23;q24), +mar karyotype. CML-T1 cells exhibit molecular changes typical of CML, including translocation of the ABL protooncogene from chromosome 9 to 22, rearrangement of the BCR gene, and transcription of a chimeric BCR-ABL messenger RNA (mRNA). The ABL insertion on chromosome 22 appears interstitial, similar to other cases of Ph-chromosome-negative CML. These data clearly indicate that T cells can be involved in acute-phase CML. CML-T1 should be useful in studying this process as well as that underlying Ph-chromosome-negative CML.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788468

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  The majority of T lymphocytes are polyclonal during the chronic phase of chronic myelogenous leukemia.

Authors:  N Tsukamoto; M Karasawa; T Maehara; K Okamoto; H Sakai; T Naruse; K Morita; J Tsuchiya; M Omine
Journal:  Ann Hematol       Date:  1996-02       Impact factor: 3.673

2.  bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.

Authors:  A G Elefanty; I K Hariharan; S Cory
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

3.  Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target.

Authors:  O Toman; T Kabickova; O Vit; R Fiser; K Machova Polakova; J Zach; J Linhartova; D Vyoral; J Petrak
Journal:  Oncol Rep       Date:  2016-07-18       Impact factor: 3.906

4.  FISH mapping of Philadelphia negative BCR/ABL1 positive CML.

Authors:  Anna Virgili; Diana Brazma; Alistair G Reid; Julie Howard-Reeves; Mikel Valgañón; Anastasios Chanalaris; Valeria As De Melo; David Marin; Jane F Apperley; Colin Grace; Ellie P Nacheva
Journal:  Mol Cytogenet       Date:  2008-07-18       Impact factor: 2.009

5.  Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia.

Authors:  L C Gillis; D M Berry; M D Minden; C J McGlade; D L Barber
Journal:  Leukemia       Date:  2013-02-12       Impact factor: 11.528

6.  Recurrent histone mutations in T-cell acute lymphoblastic leukaemia.

Authors:  Grace Collord; Inigo Martincorena; Matthew D Young; Letizia Foroni; Niccolo Bolli; Michael R Stratton; George S Vassiliou; Peter J Campbell; Sam Behjati
Journal:  Br J Haematol       Date:  2018-03-30       Impact factor: 6.998

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.